Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from McKesson

The 4 Fastest-Growing Stocks to Purchase Right Now

Markets have been highly volatile this year due to macroeconomic and geopolitical headwinds. However, signs of slowing inflation and dovish comments from the Fed Chair have renewed investor appetite for riskier assets. Hence, it could be wise to invest in the fastest-growing stocks, CVS Health (CVS), McKesson (MCK), Celestica (CLS),…

StockNews.com

1 Growth Stock That's Worth Buying Into Before 2022 Ends

The Fed’s aggressive interest rate hikes this year have hurt growth stocks significantly. However, McKesson Corporation (MCK) has stood tall, becoming the second-best performing non-energy stock in the S&P 500 this year. With its growth expected to remain strong due to its strategic acquisition of Rx Savings Solutions (RxSS), it…

StockNews.com

1 Stable Stock Warren Buffett Owns and You Should Too

World-famous investor Warren Buffett picked up shares of healthcare services provider McKesson Corporation (MCK) this year. The company has raised its dividends for 16 consecutive years. With a recession expected next year, this healthcare services stock is expected to remain stable as demand for healthcare and related services usually remain…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Stocks to Buy Now That Could Make You a Millionaire

With inflation showing signs of slowing down, markets have been buoyed by expectations of a softening monetary stance by the Fed. Hence, it could be opportune to invest in fundamentally strong stocks AT&T (T) and McKesson (MCK) with enough headroom to grow. Read on….

StockNews.com

Position Yourself for Major Growth in Q4 With These 2 Stocks

Despite the overall market uncertainty, investors could still find stocks well-poised for strong growth. To that end, McKesson (MCK) and Flowers Foods (FLO) could be solid additions to one’s portfolio this quarter, given their strong fundamentals and solid growth prospects. Read more….

StockNews.com

3 Stocks With Reasonable Upside Potential to Buy Now

The Fed’s determination to keep raising interest rates to bring inflation under control is increasing the odds of a recession. Although the stock market is expected to remain under pressure, Wall Street analysts expect a reasonable upside in McKesson Corporation (MCK), AmerisourceBergen Corporation (ABC), and TravelCenters of America (TA) in…

StockNews.com

3 Stocks With Growth Potential You Won't Want to Miss

The Federal Reserve’s single-minded battle against inflation is expected to keep the stock market volatile and the economy teetering on the brink of a recession. However, companies with resilient and profitable businesses might be able to endure the near-term challenges. Hence, we think it could be wise to invest in…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Trump Ally Dr. Oz Hyped Unapproved 'Covid Cures' From Companies He Owns Shares Of

Republican Pennsylvania Senate candidate Dr. Mehmet Oz owns shares of two companies he publicly supported, touting their drugs as potential Covid-19 treatments — even though the drugs weren't approved by the U.S. Food and Drug Administration (FDA).

Benzinga

2 Undervalued Stocks With Solid Growth Potential

As the elevated inflation and a potential hawkish Fed could keep the market under pressure, investing in McKesson (MCK) and ADT (ADT), which possess solid growth prospects and are currently trading at discounts to their peers, could be wise. Read on….

StockNews.com

Illinois Senate President Don Harmon, other pols keep taking money from pharma companies implicated in opioid crisis

The Oak Park Democrat continues to accept campaign money from Johnson & Johnson, 1 of 4 companies paying $26 billion to settle suits accusing them of fueling the crisis. He’s not the only Illinois official doing so.

Chicago Sun-Times

WVa cities, counties reach $400M settlement with drug firms

West Virginia cities and counties have reached a $400 million tentative settlement with three major U.S. drug distributors

The Independent UK

3 Winning Healthcare Stocks to Buy for the Rest of the Summer

Increased health awareness and the rapidly aging population are expected to drive the growth of healthcare companies. Healthcare stocks Cigna Corp. (CI), Humana (HUM), and McKesson Corp. (MCK) have bucked the market downtrend and are in momentum. Since the market is expected to remain under pressure in the near term,…

StockNews.com

Buffett Just Stocked up on These 3 Buy-Rated Stocks

Warren Buffett has been one of the most influential investors of all time. His careful methodology in picking stocks has made him a consistently successful investor. So, we think Warren Buffett stocks Occidental Petroleum (OXY), Celanese (CE), and McKesson (MCK), which are also rated Strong Buy or Buy in our…

StockNews.com

Here's How Much You Would Have Made Owning McKesson Stock In The Last 20 Years

McKesson (NYSE:MCK) has outperformed the market over the past 20 years by 5.66% on an annualized basis producing an average annual return of 12.71%. Currently, McKesson has a market capitalization of $46.56 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today

McKesson (NYSE:MCK) has outperformed the market over the past 10 years by 2.06% on an annualized basis producing an average annual return of 12.64%. Currently, McKesson has a market capitalization of $44.39 billion.

Benzinga

Where McKesson Stands With Analysts

Over the past 3 months, 5 analysts have published their opinion on McKesson (NYSE:MCK) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

Upgrades

Benzinga

$1000 Invested In McKesson 15 Years Ago Would Be Worth This Much

McKesson (NYSE:MCK) has outperformed the market over the past 15 years by 4.74% on an annualized basis producing an average annual return of 11.75%. Currently, McKesson has a market capitalization of $46.98 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Executives Sell Over $100M Of 4 Stocks

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

What Is Happening With Endo Shares Today

Endo International Plc (NASDAQ:ENDP) initiated negotiations with its lenders and senior bondholders regarding a possible reorganization of more than $8 billion of its debt, the Wall Street Journal reported, citing people familiar with the matter. Lenders began talks after the company reported disappointing earnings early this month for 1Q 2022, driven by the loss…

WEKU

Idaho announces $119 million opioid crisis settlement

Idaho Gov. Brad Little and Attorney General Lawrence Wasden say it's the second-largest consumer settlement in state history.

The Independent UK

Idaho announces $119 million opioid crisis settlement

Idaho officials have announced a $119 million settlement with drugmaker Johnson & Johnson and three major distributors over their role in the opioid addiction crisis

Benzinga

4 Analysts Have This to Say About McKesson

McKesson (NYSE:MCK) has observed the following analyst ratings within the last quarter:

Benzinga

Here's How Much You Would Have Made Owning McKesson Stock In The Last 5 Years

McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 6.7% on an annualized basis producing an average annual return of 17.83%. Currently, McKesson has a market capitalization of $49.19 billion.

Benzinga

Why McKesson Shares Are Jumping Today

McKesson Corp (NYSE:MCK) reported Q4 FY22 adjusted EPS of $5.83, +15% Y/Y, and missing the consensus of $6.04. Revenues increased 12% Y/Y to $66.10 billion, surpassing the consensus of $63.61 billion. U.S. Pharmaceutical segment's Q4 FY22 revenues were $53.67 billion, +14%, driven by an increased volume of specialty products, including higher volumes…

1 2 3 4

People

Dipanjan BanchurSince

722 stories

Pat Nabong

621 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.